(-)-7′-isothiocyanato-11-hydroxy-1′,1′- dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor

Molecular Pharmacology

Volumn 68, Issue 6, 2005, Pages 1623-1635

  Picone, Robert P ^a   Khanolkar, Atmaram D ^a   Xu, Wei ^a,d   Ayotte, Lionel A ^a   Thakur, Ganesh A ^a   Hurst, Dow P ^b   Abood, Mary E ^c   Reggio, Patricia H ^b   Fournier, Donna J ^a   Makriyannis, Alexandros ^a,d  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXY 1',1' DIMETHYLHEPTYLHEXAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 7 BROMO 11 HYDROXY 1',1' DIMETHYLHEPTYLHEXAHYDROCANNABINOL; 7' ISOTHIOCYANATO 11 HYDROXY 1',1' DIMETHYLHEPTYLHEXAHYDROCANNABINOL; ALANINE; AM 4056; AM 841; AMINO ACID; CANNABINOID 1 RECEPTOR; CANNABINOL DERIVATIVE; CYSTEINE; DRONABINOL; ISOTHIOCYANIC ACID; LEUCINE; SERINE; UNCLASSIFIED DRUG; 7'-ISOTHIOCYANATO-11-HYDROXY-1',1'-DIMETHYLHEPTYLHEXAHYDROCANNABINOL; CANNABINOL; DRUG DERIVATIVE; LIGAND; TETRAHYDROCANNABINOL;

AFFINITY LABELING; ANIMAL CELL; ARTICLE; BINDING AFFINITY; COVALENT BOND; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LIGAND BINDING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; ELECTRICITY; GENETICS; METABOLISM; SITE DIRECTED MUTAGENESIS;

AFFINITY LABELS; BINDING SITES; CANNABINOL; CYSTEINE; ELECTROSTATICS; HUMANS; LIGANDS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 27844505656     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.014407     Document Type: Article

References (45)

1. Abadji V, Lucas-Lenard JM, Chin C, and Kendall DA (1999) Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J Neurochem 72:2032-2038.
2. Andersson H, D'Antona AM, Kendall DA, Von Heijne G, and Chin CN (2003) Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol Pharmacol 64:570-577.
3. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, and Javitch JA (2001) Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276:29171-29177.
4. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 25:366-428.
5. Barnett-Norris J, Hurst DP, Buehner K, Ballesteros JA, Guarnieri F, and Reggio PH (2002) Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation. Int J Quantum Chem 88:76-86.
6. Bockaert J and Pin JP (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO (Eur Mol Biol Organ) J 18:1723-1729.
7. Bramblett RD, Panu AM, Ballesteros JA, and Reggio PH (1995) Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci 56:1971-1982.
8. Charalambous A, Yan G, Houston DB, Howlett AC, Compton DR, Martin BR, and Makriyannis A (1992) 5′-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor. J Med Chem 35:3076-3079.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Chin CN, Lucas-Lenard J, Abadji V, and Kendall DA (1998) Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem 70:366-373.
11. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274:768-770.
12. Fay JF, Dunham TD, and Farrens DL (2005) Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 44:8757-8769.
13. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, and Kobilka BK (1997) Agonists induce conformational changes in transmembrane domains and VI of the β2 adrenoceptor. EMBO (Eur Mol Biol Organ) J 16:6737-6747.
14. Ghanouni P, Steenhuis JJ, Farrens DL, and Kobilka BK (2001) Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor. Proc Natl Acad Sci USA 98:5997-6002.
15. Guo Y, Abadji V, Morse KL, Fournier DJ, Li X, and Makriyannis A (1994) (-)-11-Hydroxy-7′-isothiocyanato-1′,1′-dimethylheptyl-delta 8-THC: a novel, highaffinity irreversible probe for the cannabinoid receptor in the brain. J Med Chem 37:3867-3870.
16. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
17. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, and Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875-3877.
18. Hulme EC, Lu ZL, Ward SD, Allman K, and Curtis CA (1999) The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Eur J Pharmacol 375:247-260.
19. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, and Reggio PH (2002) N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide (SR141716A) interaction with Lys 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62:1274-1287.
20. Javitch JA, Fu D, Liapakis G, and Chen J (1997) Constitutive activation of the β2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 272:18546-18549.
21. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, and Gether U (2001) Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the β2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 276:9279-9290.
22. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, and Makriyannis A (1999) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42:769-776.
23. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
24. Luk T, Jin W, Zvonok A, Lu D, Lin XZ, Chavkin C, Makriyannis A, and Mackie K (2004) Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 142:495-500.
25. Martin BR, Jefferson R, Winckler R, Wiley JL, Huffman JW, Crocker PJ, Saha B, and Razdan RK (1999) Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists and antagonists. J Pharmacol Exp Ther 290:1065-1079.
26. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, and Abood ME (2004) Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem 279:48024-48037.
27. 1 receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46:5139-5152.
28. McAllister SD, Tao Q, Barnett-Norris J, Buehner K, Hurst DP, Guarnieri F, Reggio PH, Nowell Harmon KW, Cabral GA, and Abood ME (2002) A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol 63:2121-2136.
29. Morse KL, Fournier DJ, Li X, Grzybowska J, and Makriyannis A (1995) A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci 56:1957-1962.
30. Muller G (2000) Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. Curr Med Chem 7:861-888.
31. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le TI, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (Wash DC) 289:739-745.
32. Palmer SL, Thakur GA, and Makriyannis A (2002) Cannabinergic ligands. Chem Phys Lipids 121:3-19.
33. Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, and Makriyannis A (1998) Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1′-substituted delta 8-tetrahydrocannabinols. J Med Chem 41:1195-1200.
34. Picone RP, Fournier DJ, and Makriyannis A (2002) Ligand based structural studies of the CB1 cannabinoid receptor. J Pept Res 60:348-356.
35. Reggio PH, Panu AM, and Miles S (1993) Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach. J Med Chem 36:1761-1771.
36. Rosenthal HE (1967) A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem 20:525-537.
37. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, and Javitch JA (2002) β2 Adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 277:40989-40996.
38. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, and Ferrara P (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 65:627-635.
39. Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Le Fur G, Caput D, and Ferrara P (1996) Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem 271:6941-6946.
40. Song ZH and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891-896.
41. Tahtaoui C, Balestre MN, Klotz P, Rognan D, Barberis C, Mouillac B, and Hibert M (2003) Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfhydryl-reactive ligands and cysteine mutants as chemical sensors. J Biol Chem 278:40010-40019.
42. Tao Q and Abood ME (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285:651-658.
43. Tao Q, McAllister SD, Andreassi J, Nowell KW, Cabral GA, Hurst DP, Bachtel K, Ekman MC, Reggio PH, and Abood ME (1999) Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol Pharmacol 55:605-613.
44. Yeagle PL, Danis C, Choi G, Alderfer JL, and Albert AD (2000) Three dimensional structure of the seventh transmembrane helical domain of the G-protein receptor, rhodopsin. Mol Vis 6:125-131.
45. Zhu J, Yin J, Law PY, Claude PA, Rice KC, Evans CJ, Chen C, Yu L, and Liu-Chen LY (1996) Irreversible binding of cis-(+)-3-methylfentanyl isothiocyanate to the δ-opioid receptor and determination of its binding domain. J Biol Chem 271:1430-1434.